Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

oxybutynin

Known as: Oxybutyninum, 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate, 4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate 
A tertiary amine possessing antimuscarinic and antispasmodic properties. Oxybutynin blocks muscarinic receptors in smooth muscle, hence inhibiting… Expand
National Institutes of Health

Related topics

Related topics

32 relations
24 HR Oxybutynin chloride 10 MG Extended Release Oral Tablet84 HR oxybutynin 0.162 MG/HR Transdermal System [Oxytrol]Drug AllergyGlaucoma
Expand

Narrower (13)

DitropanDriptaneOxyb AbZOxybutin Holsten
Expand

Broader (4)

Mandelic AcidsMuscarinic AntagonistsParasympatholyticsUrological Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder
ABSTRACT Antimuscarinic agents are now widely used as the pharmacological therapy for overactive bladder (OAB) because neuronal… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2012
Highly Cited
2012
Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience
Study Type – Therapy (prevalence) 
Highly Cited
2010
Highly Cited
2010
Investigation of the mechanism of C(sp3)-H bond cleavage in Pd(0)-catalyzed intramolecular alkane arylation adjacent to amides and sulfonamides.
The reactivity of C(sp(3))-H bonds adjacent to a nitrogen atom can be tuned to allow intramolecular alkane arylation under Pd(0… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2006
Highly Cited
2006
Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.
OBJECTIVES To investigate the effects of darifenacin controlled-release (CR) and oxybutynin extended-release (ER) on cognitive… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2003
Highly Cited
2003
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.
OBJECTIVES To compare the efficacy and safety of an oxybutynin transdermal delivery system (OXY-TDS) and oral, long-acting… Expand
Highly Cited
2001
Highly Cited
2001
Effects of Tolterodine, Trospium Chloride, and Oxybutynin on the Central Nervous System
Antimuscarinic compounds are increasingly used to treat the symptoms of overactive bladder; however, their use is often… Expand
Highly Cited
1999
Highly Cited
1999
Clinical Efficacy and Safety of Tolterodine Compared to Oxybutynin and Placebo in Patients with Overactive Bladder
Abstract: This study compared the clinical efficacy (determined from micturition diaries) and safety of 12 weeks’ treatment with… Expand
  • table 1
  • table 2
  • figure 2
  • figure 3
  • figure 4
Highly Cited
1998
Highly Cited
1998
Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder
Objective  To compare the efficacy and tolerability of tolterodine with that of oxybutynin in patients with an overactive… Expand
Highly Cited
1995
Highly Cited
1995
Xerostomia, Xerogenic Medications and Food Avoidances in Selected Geriatric Groups
OBJECTIVE: To study the relationship between complaints of xerostomia and salivary performance and food avoidances in four… Expand
Highly Cited
1991
Highly Cited
1991
Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo.
Clinical efficacy and adverse effects of oxybutynin and propantheline in the treatment of symptoms related to detrusor… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE